Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Spyre (NASDAQ: SYRE) reported 12-week Part A induction results from the Phase 2 SKYLINE trial for SPY001 in moderate-to-severe ulcerative colitis. SPY001 met the primary endpoint with a -9.2 point RHI change (p<0.0001) at Week 12.
Key secondary results: clinical remission 40%, endoscopic improvement 51%, change in modified Mayo score -3.7. Safety was described as consistent with the α4β7 class; one SAE (2%) deemed not drug-related. Part A recruitment closed; Part B enrollment is open with monotherapy and combination cohorts, and additional Part A readouts expected mid-2026 to Q3 2026.
Spyre Therapeutics (NASDAQ: SYRE) will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severe ulcerative colitis on Monday, April 13, 2026.
The company will host a conference call and webcast at 8:00am ET on April 13, 2026 to discuss the results; archived access will be available via Spyre's Investor Relations site.
Spyre Therapeutics (NASDAQ: SYRE) announced inducement stock option awards totaling 70,200 shares to five non-executive employees, approved April 1, 2026, under the 2018 Equity Inducement Plan. The options have a 10-year term and an exercise price of $48.90 (Nasdaq close April 1, 2026).
Vesting is one-fourth after the first anniversary of each employee’s start date and thereafter monthly at one-forty-eighth, subject to continuous service and the terms of the 2018 Plan. Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Spyre (NASDAQ: SYRE) announced completion of recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial and accelerated the expected Week 12 topline readout to Q3 2026. Recruitment for psoriatic arthritis and axial spondyloarthritis sub-studies remains on track with Week 16 readouts expected in Q4 2026. The SKYLINE ulcerative colitis platform continues to enroll ahead of schedule, with Part A readouts to begin in Q2 2026. Management said this schedule could produce sequential key data across IBD and rheumatic programs each quarter.
Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 46,600 shares granted to two non-executive employees under the 2018 Plan. The grants were approved March 2, 2026 and comply with Nasdaq Listing Rule 5635(c)(4).
The options carry a 10-year term, an exercise price of $42.49 per share (closing price on March 2, 2026), and vest 25% after one year then monthly at 1/48th thereafter, subject to continuous service and plan terms.
Spyre Therapeutics (NASDAQ: SYRE) announced management will participate in three investor conferences in March 2026: TD Cowen Health Care (Boston) on March 3, Leerink Global Healthcare (Miami) on March 9, and Jefferies Biotech on the Beach (Miami) on March 10.
Management will host one-on-one investor meetings and provide live audio webcasts and replays via the company investor events website.
Spyre Therapeutics (NASDAQ:SYRE) reported Q4 and full-year 2025 results and corporate updates on Feb 19, 2026. Key highlights: $756.5 million in cash and marketable securities as of Dec 31, 2025, expected runway into H2 2028; six proof-of-concept readouts planned in 2026 across SKYLINE and SKYWAY.
The company advanced SPY001, SPY002, SPY003, and SPY072 into Phase 2 trials, raised gross proceeds of $316.2 million in Oct 2025, and appointed a new Chief Commercial Officer.
Spyre Therapeutics (NASDAQ: SYRE) announced scientific presentations at the 21st ECCO Congress (Feb 18-21, 2026) covering interim Phase 1 results for SPY003, the SKYLINE platform trial, and preclinical mouse data showing dual TL1A/IL-23 targeting outperformed monotherapies.
SPY003 was well tolerated to 20 weeks, showed a differentiated PK profile consistent with Q3M or Q6M dosing, and reduced downstream cytokines.
Spyre Therapeutics (NASDAQ: SYRE) granted inducement stock options totaling 30,200 shares to five non-executive employees under its 2018 Equity Inducement Plan.
Approved on Feb 2, 2026, the options have a 10-year term, $32.75 exercise price (Feb 2 close) and vest 25% after one year then monthly at 1/48th, subject to continuous service.
Spyre Therapeutics (NASDAQ: SYRE) announced that its Compensation Committee approved inducement stock options to purchase 108,155 shares for employee Kate Chevlen in connection with her appointment as Chief Commercial Officer.
The grant was approved on January 22, 2026, provided under the 2018 Equity Inducement Plan, and was disclosed as material to the employee's acceptance under Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $34.09, equal to Spyre's Nasdaq closing price on January 22, 2026. Vesting is 1/4 on the first anniversary of the start date, then 1/48 monthly thereafter, subject to continuous service and the 2018 Plan terms.